Artemin

Unknown Manufacturer

Artemin is under investigation in clinical trial NCT01842126 (Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)).

Overview

Artemin is under investigation in clinical trial NCT01842126 (Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)).

Technical identifiers

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

ANTI-NEOPLASTIC USES OF ARTEMIN ANTAGONISTS
Applicant: LOBIE PETER EDWARDPriority: 2010
CN
US
3 publications
HUMAN ANTIBODIES TO ARTEMIN AND METHODS OF USE THEREOF
Applicant: REGENERON PHARMAPriority: 2021
CN
EP
US
WO
7 publications
Inhibitors of the Artemin Pathway for Treatment of Cancer
Applicant: UNIV CHICAGOPriority: 2020
US
WO
2 publications
Use of artemin, a member of the GDNF ligand family
Applicant: SHELTON DAVID LPriority: 2000
CN
US
3 publications
ANTIBODY TARGETING ARTEMIN, PREPARATION METHOD THEREFOR, AND USE THEREOF IN TUMOR TREATMENT
Applicant: SUZHOU INST OF SYSTEMS MEDICINEPriority: 2023
CN
WO
2 publications
POLYPEPTIDES AND POLYNUCLEOTIDES FOR ARTEMIN AND RELATED LIGANDS, AND METHODS OF USE THEREOF
Applicant: DONGXU LIUPriority: 2008
CN
US
3 publications
PREVENTION AND TREATMENT OF HEADACHES
Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 3 LTDPriority: 2023
US